Daewoong Bio, a company specializing in brain health, announced on April 13 that it will launch a 5mg low-dose version of “Glivix” (active ingredient: memantine hydrochloride), a treatment for Alzheimer’s-type dementia.


Daewoong Bio Glibixa Full Dosage Product. Daewoong Bio

Daewoong Bio Glibixa Full Dosage Product. Daewoong Bio

View original image

With this launch, Glivix now offers a full dosage lineup for memantine formulations, including the existing 10mg and 20mg products. The company explained that this allows healthcare professionals to make more detailed prescriptions based on the patient’s symptoms, tolerability, and kidney function.


Glivix recorded a compound annual growth rate (CAGR) of 18% from 2021 to 2025. Currently, it ranks second overall among memantine-based prescription drugs in terms of out-of-hospital prescription volume, and it holds the top spot in the generic market, excluding the original product. Daewoong Bio plans to accelerate prescription expansion with the completion of its full dosage lineup.


The company also aims to maximize synergy with its central nervous system (CNS) product portfolio, which includes “Gliatamin,” “Cerebrain,” and “Beacept.” By doing so, Daewoong Bio intends to establish a “total solution” in the dementia treatment field and further solidify its position as a leading brain health company.


The main ingredient of Glivix, memantine hydrochloride, works by regulating the excessive activity of the neurotransmitter “glutamate,” which is associated with Alzheimer’s-type dementia. This helps prevent brain cell damage and improves cognitive function. However, side effects such as dizziness, headache, and drowsiness may occur in the initial phase of administration, requiring careful dose adjustment.


Accordingly, memantine formulations are administered by starting at 5mg initially and gradually increasing the dose over three weeks to minimize the risk of adverse reactions. For patients with moderate or more severe renal impairment, it is essential to reduce the daily dose to 10mg, which has led to consistent demand for low-dose products.


The company expects that Glivix 5mg will provide a safe dosing option for patients at the initial treatment stage or those with moderate renal impairment, significantly improving tolerability.



Jin Sungon, CEO of Daewoong Bio, stated, “With the launch of Glivix 5mg, we have strengthened the foundation for precision treatment tailored to each patient’s condition from the initial dose escalation to maintenance therapy. Based on the synergy with our existing CNS product lineup, we will provide even broader solutions across the entire spectrum of dementia treatment.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing